論文

査読有り 国際誌
2022年8月

Cumulative risk of developing a new symptom in patients with primary biliary cholangitis and its impact on prognosis.

JGH open : an open access journal of gastroenterology and hepatology
  • Naruhiro Kimura
  • Toru Setsu
  • Yoshihisa Arao
  • Norihiro Sakai
  • Yusuke Watanabe
  • Hiroyuki Abe
  • Hiroteru Kamimura
  • Akira Sakamaki
  • Takeshi Yokoo
  • Kenya Kamimura
  • Atsunori Tsuchiya
  • Akihiko Osaki
  • Kentarou Igarashi
  • Nobuo Waguri
  • Masahiko Yanagi
  • Toru Takahashi
  • Soichi Sugitani
  • Yuka Kobayashi
  • Masaaki Takamura
  • Akira Yoshikawa
  • Toru Ishikawa
  • Toshiaki Yoshida
  • Toshiaki Watanabe
  • Hitoshi Bannai
  • Tomoyuki Kubota
  • Kazuhiro Funakoshi
  • Hiroto Wakabayashi
  • So Kurita
  • Norio Ogata
  • Masashi Watanabe
  • Yuhsaku Mita
  • Shigeki Mori
  • Motoya Sugiyama
  • Toru Miyajima
  • Sumio Takahashi
  • Shuichi Sato
  • Kisei Ishizuka
  • Hironobu Ohta
  • Yutaka Aoyagi
  • Shuji Terai
  • 全て表示

6
8
開始ページ
577
終了ページ
586
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1002/jgh3.12789

Background and Aim: Symptoms of primary biliary cholangitis (PBC) frequently impair one's quality of life (QOL). Nonetheless, with improved treatment, the prognosis of PBC also improves. QOL plays an important role in patients with PBC. In this study, we aimed to reevaluate the transition of new symptom development in PBC and its predictive factors. Methods: This retrospective multicenter study enrolled 382 patients with PBC for symptom analysis. The impact of a newly developed symptom on PBC prognosis was investigated by Kaplan-Meier analysis with propensity score matching and logistic progression analysis. Results: The cumulative risk of developing a new symptom after 10 and 20 years of follow-up was 7.6 and 28.2%, and specifically that of pruritus, which was the most common symptom, was 6.7 and 23.3%, respectively. In Cox hazard risk analysis, serum Alb level (hazard ratio [HR], 1.097; 95% confidence interval [CI], 1.033-1.165; P = 0.002), the serum D-Bil level (HR, 6.262; 95% CI, 2.522-15.553, P < 0.001), and Paris II criteria (HR, 0.435; 95% CI, 0.183-1.036; P = 0.037) were significant independent predictors of a new symptom. Kaplan-Meier analysis showed that the overall survival and liver-related death were not significant between patients with and without a new symptom. Conclusion: The cumulative risk of new symptom development is roughly 30% 20 years after diagnosis and could be predicted by factors including serum albumin levels, serum D-Bil level, and Paris II criteria.

リンク情報
DOI
https://doi.org/10.1002/jgh3.12789
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/35928695
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344586
ID情報
  • DOI : 10.1002/jgh3.12789
  • PubMed ID : 35928695
  • PubMed Central 記事ID : PMC9344586

エクスポート
BibTeX RIS